Article Text
Statistics from Altmetric.com
We read with interest the recent article by Lennard on the role of thiopurine methyltransferase (TPMT) enzyme in predicting azathioprine related toxicity in patients with inflammatory bowel disease (IBD) (Gut 2002;51:143–6). He concludes that measurement of TPMT activity has no specific role in identifying the risk of significant bone marrow toxicity in long term users of azathioprine. This conclusion is in agreement with other published work and emphasises the importance of ongoing haematological monitoring in IBD patients receiving this drug.1 The importance of haematological monitoring in the early detection and prevention of azathioprine related toxicity is well recognised.2 However, the duration of early monitoring is a matter of controversy. The current British National Formulary guidelines recommend that patients undergo blood tests on at least a weekly basis for the initial four weeks of therapy. The drug’s manufacturers recommend a more stringent monitoring policy and in their view, initial monitoring should continue for the first eight weeks of treatment. The American College of Gastroenterology guidelines recommend a slightly different approach, with fortnightly blood counts for the initial three months of therapy.3 The key issue in determining the value of these different approaches to monitoring is the time of onset of potentially life threatening bone marrow suppression following initiation of azathioprine treatment. These data are not available for patients with IBD.
In a retrospective study, we analysed the time of onset of all drug related toxicity …